US Patent No. US 8,722,093 B2

A method of increasing serum vitamin C level in a subject
A method of inhibiting NF-κB protein level in a subject
A method of increasing adiponectin level in a subject
A method of reducing TNF alpha level in a subject

US Patent No. US 9,006,292 B2

A method of treating a skin disease in a subject, comprising: psoriasis, atopic dermatitis, contact dermatitis and other eczematous dermatitis’s, seborrhoeic dermatitis, neurodermatitis, decubitus, lichen planus, pemphigus, bullate pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythema, cutaneous, eosinophilias, lupus erythematosuseczema, and MRSA, basal cell carcinoma.

A method of treating a disease by improving a physiologic or metabolic parameter in a subject. The said method comprising: Increasing serum APO A1 protein, hemoglobin, platelet count; Reducing lipoprotein-a, uric acid, elevated AST:ALT ratio, ferritin, bilirubin, PTH, calcium, creatinine, alkaline phosphatase, BUN, phosphorus levels; Regulating eGFR level, neutrophils, monocytes, white blood cell, thyroid hormone (TSH).

The method of claim wherein said disease is: kidney disease, MRSA infection, MDS, hematological disease, prostate cancer, and eczema.

US Patent No. US 9,034,383 B2

The present invention provides methods of using these nanoparticles and formulations to treat and prevent disease and to regulate metabolism. In various embodiments, the nanoparticles of the invention are of use to regulate hypertension, cholesterol metabolism and treat hyperlipidemia, hypercholesterolemia, inflammation, etc. In various embodiments, the formulations are use to regulate or reduce protein oxidation. In an exemplary embodiment, the formulation are of use to manage glycemic levels by reducing, insulin resistance, diabetes, and other conditions related to blood sugar levels. In still further embodiments, the formulations are of use to regulate, e.g., increase, plasma vitamin C levels and to reduce systolic and diastolic blood pressure. In other embodiments, the formulations are of use to inhibit PAI-1 (Plasminogen activation inhibitor). In other embodiments the formulations are of use in increasing DDP-IV that could be useful in cancer treatment.